Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction

Recruiting now · Not applicable

Conditions studied: Benign Prostatic Hyperplasia

In brief

It has been demonstrated that sexual activity was common in the majority of men over 50 years old and was an important component of overall quality of life (QoL). Ejaculatory dysfunction (EjD) is the most common side effect of surgical treatment of benign prostatic obstruction (BPO). It has been considered for decades to be an inevitable consequence of restoring micturition comfort. EjD can have a substantial deleterious effect on the QoL of men with previously maintained regular sexual activity, inducing decreased orgasmic intensity and increased levels of anxiety and depression. A better understanding of the physiology of ejaculation has enabled the emergence of modified surgical techniques that aim to preserve antegrade ejaculation. Our hypothesis is that conservation of ejaculation can be achieved by modified surgical procedures without compromising functional outcomes.

Key facts

Study ID

NCT05574244

Run by

University Hospital, Bordeaux

People needed

336

Starts

2022-09-29

Expected to finish

2029-03-31

Last updated by the study team

2026-04-09

Who can join

Age: 40 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Man over 40 years old
• Indication of surgical management for BPH
• Prostate volume ≥30 cc and ≤150 cc as evaluated by ultrasonography ( or an MRI if available)
• IPSS score ≥12
• Qmax ≤15 ml/s
• Affiliated to French national social security system
• wish and be able to comply with planned visits
• Able to express his consent
• Signed informed consent form

You may not qualify if…

• Unwillingness to accept the treatment
• No pre-operative ejaculation or sexuality
• Neurological pathology responsible for micturition disorders
• History of prostatic surgery
• Stenosis of the urethra symptomatic
• History of prostate cancer
• History of radiotherapy or pelvic surgery
• Patient refusing the principle of partial surgery
• Life expectancy <3 years
• Inability to understand the informed consent document, to give consent voluntarily or to complete the study tasks.
• Participation in another clinical study involving an investigational product within 1 month before study entry.

Where it is running

• Hopital Privé de Versailles, Clinique des Franciscaines — Versailles, France (enrolling)
• CHU Angers — Angers, France (enrolling)
• Centre Hospitalier Universitaire de Bordeaux — Bordeaux, France (enrolling)
• Hôpital Privé des Côtes D'Armor — Plérin, France (enrolling)
• CHU de Reims- Hôpital Robert Debré — Rennes, France (enrolling)
• CHU de Rennes — Rennes, France (enrolling)
• CH Pays d'Aix — Aix-en-Provence, France (enrolling)
• CHU de Limoges — Limoges, France (enrolling)
• Hôpital Nord Marseille — Marseille, France (enrolling)
• Polyclinique Saint George — Nice, France (enrolling)
• Hôpital cochin — Paris, France (enrolling)
• Hôpital Prive Francheville — Périgueux, France (enrolling)
• Hôpital Lyon Sud HCl Bât.3C Centre Hospitalier Lyon Sud — Pierre-Bénite, France (enrolling)
• CHU Mondor — Créteil, France
• Hôpital Claude Huriez — Lille, France
• CHRU Hôpitaux de tours — Tours, France
• Clinique Pasteur — Toulouse, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.